OP0356 Plasmablast proliferation is associated with toll like receptor 7 polymorphisms and upregulation of type i interferon, contributing to the antibody production in antiphospholipid syndrome
Authors: R. Hisada, M. Kato, E. Sugawara, Y. Fujieda, K. Oku, T. Bohgaki, O. Amengual, S. Yasuda, T. Atsumi
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Antiphospholipid antibodies (aPL) as pathogenic autoantibodies in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are supported by a number of clinical, <i>ex vivo</i> and animal studies. Nevertheless, aPL are not eliminated by corticosteroid administration or immunosuppression. Novel therapy targeting aPL production is currently unmet needs, in contrast, little is known on its pathological mechanism. <h3>Objectives</h3> This study aimed to clarify the mechanism of aPL production by lymphocyte subset analysis, genomic analysis and <i>ex vivo</i> experiments. <h3>Methods</h3> B cell and T cell subsets, a total of 21 subsets, were evaluated in peripheral blood mononuclear cells (PBMC) of 26 primary APS (PAPS), 18 SLE-associated APS (SLE/APS) patients and 10 healthy controls by flow cytometry. Twenty-one single nucleotide polymorphisms (SNP), which were shown to be associated with autoimmune or thrombotic diseases, were analysed in genomic DNA of those patients by TaqMan genotyping assay. Interferon (IFN) score was calculated based on the mRNA expression of Ly6e, Mx1, IFIT1 and IFIT3 in PBMC. To evaluate the aPL-producing capability of plasmablasts, PBMC obtained from APS patients were cultured following depletion of CD19 +CD20+or CD19+CD20 cells and the culture supernatants were applied to aPL measurements by enzyme-linked immunosorbent assay and cell assay using β2GPI/HLA-DR7 overexpressing HEK293T cells.<sup>1</sup> <h3>Results</h3> In PAPS and SLE/APS patients, plasmablasts, Th2 cells and Th17 cells were increased while pre- and post- switched memory B cells, regulatory B cells and regulatory T cells were decreased compared to healthy controls. Genomic analysis revealed that the increase of plasmablasts (p=0.032) and the decrease of memory B cells (p=0.013) were more pronounced in patients with a risk allele of SNP in toll like receptor 7 (TLR7) gene (rs3853839). IFN score was significantly higher in the TLR7 SNP risk allele carriers, confirming the downstream signalling of TLR7 (p=0.029). <i>Ex vivo</i> experiments showed that aPL, including anti-cardiolipin/β2-glycoprotein I-HLA class II complexes -IgG and -IgM, were present in the culture supernatant of CD19 +CD20+depleted PBMC from APS patients, but not in that of CD19 +CD20 depleted cells. <h3>Conclusions</h3> Our data indicate an important role of plasmablasts in the production of aPL. Furthermore, plasmablast proliferation was associated with TLR 7 and type I IFN, suggesting a common pathophysiology in SLE and APS. Targeting plasmablasts might be a novel, immunological therapeutic approach in the treatment of APS. <h3>Reference</h3> [1] Tanimura K, et al. β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. Blood2015. <h3>Disclosure of Interest</h3> None declared